The Influence of hormonal therapy on bone tissue: myths and reality

Cover Page

Abstract


The paper presents a review of the current literature on the impact of estrogen, progesterone, and estrogen-progestin drugs (combined oral contraceptives, drugs for menopausal hormone therapy), thyroid, and glucocorticoid hormones on bone tissue. In this review, we discuss the pathogenetic mechanisms of the effects of various bioactive compounds on bone, and the results of domestic and foreign research.


Maria A. Shalina

Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott

Author for correspondence.
Email: amarus@inbox.ru

Russian Federation, Saint Petersburg

MD, PhD, the Head of the Menopause and Women’s Health Center. The Department of Endocrinology of Reproduction

Maria I. Yarmolinskaya

Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott

Email: m.yarmolinskaya@gmail.com

Russian Federation, Saint Petersburg

MD, PhD, DSci (Medicine), Professor of the Russian Academy of Sciences, the Head of the Department of Endocrinology of Reproduction, the Head of the Diagnostics and Treatment of Endometriosis Center

Elena I. Abashova

Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott

Email: abashova@yandex.ru

Russian Federation, Saint Petersburg

MD, PhD, Senior Researcher. The Department of Endocrinology of Reproduction

  • Compston JE. Sex steroids and bone. Physiol Rev. 2001;81(1):419-447. doi: 10.1152/physrev.2001.81.1.419.
  • Riggs BL, Khosla S, Melton LJ, 3rd. Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev. 2002;23(3):279-302. doi: 10.1210/edrv.23.3.0465.
  • Hendrickx G, Boudin E, Van Hul W. A look behind the scenes: the risk and pathogenesis of primary osteoporosis. Nat Rev Rheumatol. 2015;11(8):462-474. doi: 10.1038/nrrheum.2015.48.
  • Дедов И.И., Рожинская Л.Я., Марова Е.И. Первичный и вторичный остеопороз: патогенез, диагностика, принципы профилактики и лечения. - М., 2002. [Dedov II, Rozhinskaya LY, Marova EI. Primary and secondary osteoporosis: pathogenesis, diagnosis, principles of prevention and treatment. Moscow; 2002. (In Russ.)]
  • Иловайская И.А., Лазебник Л.Б., Зекцер В.Ю., и др. Состояние минерального обмена и минеральная плотность кости у пациенток с центральным гипогонадизмом как показатели преждевременного старения // Остеопороз и остеопатии. - 2015. - № 1. - C. 10-13. [Ilovayskaya IA, Lazebnik LB, Zektser VY, et al. Mineral metabolism and bone mineral density in patients with central hypogonadism as indicators of premature aging. Osteoporosis and Bone Diseases. 2015;(1):10-13. (In Russ.)]
  • Руководство по остеопорозу / Под ред. Л.И. Беневоленской. - М.: БИНОМ, 2003. [A guide to osteoporosis. Ed by L.I. Benevolenskaya. Moscow: BINOM; 2003. (In Russ.)]
  • Balasch J. Sex steroids and bone: current perspectives. Hum Reprod Update. 2003;9(3):207-222. doi: 10.1093/humupd/dmg017.
  • Зазерская И.Е. Остеопенический синдром у женщин с гипоэстрогенемией (патогенез, диагностика, лечение): Aвтореф. дис. … д-ра мед. наук. - СПб., 2006. [Zazerskaya IE. Osteopenic syndrome in women with hypoestrogenemia (pathogenesis, diagnosis, treatment). [dissertation] Saint Petersburg, 2006. (In Russ.)]
  • Shea KL, Gavin KM, Melanson EL, et al. Body composition and bone mineral density after ovarian hormone suppression with or without estradiol treatment. Menopause. 2015;22(10):1045-1052. doi: 10.1097/GME.0000000000000430.
  • Komm B, Terpening C, Benz D, et al. Estrogen binding, receptor mRNA, and biologic response in osteoblast-like osteosarcoma cells. Science. 1988;241(4861):81-84. doi: 10.1126/science.3164526.
  • Eriksen E, Colvard D, Berg N, et al. Evidence of estrogen receptors in normal human osteoblast-like cells. Science. 1988;241(4861):84-86. doi: 10.1126/science.3388021.
  • Weitzmann MN, Pacifici R. Estrogen deficiency and bone loss: an inflammatory tale. J Clin Invest. 2006;116(5):1186-1194. doi: 10.1172/JCI28550.
  • Шварц Г.Я. Фармакотерапия остеопороза (лекарственные средства для лечения и профилактики). - М., 2002. [Shvarts GY. Pharmacotherapy of osteoporosis (medicines for treatment and prevention). Moscow; 2002. (In Russ.)]
  • Hall JM, McDonnell DP. The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalphatranscriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology. 1999;140(12):5566-5578.
  • Srivastava S, Toraldo G, Weitzmann MN, et al. Estrogen decreases osteoclast formation by down-regulating receptor activator of NF-kappa B ligand (RANKL)-induced JNK activation. J Biol Chem. 2001;276(12):8836-8840. doi: 10.1074/jbc.M010764200.
  • Riggs BL, Khosla S, Melton LJ, 3rd. Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev. 2002;23(3):279-302. doi: 10.1210/edrv.23.3.0465.
  • Tsurusaki K, Ito M, Hayashi K. Differential effects of menopause and metabolic disease on trabecular and cortical bone assessed by peripheral quantitative computed tomography (pQCT). Br J Radiol. 2000;73(865):14-22. doi: 10.1259/bjr.73.865.10721315.
  • Brown M. Skeletal muscle and bone: effect of sex steroids and aging. Adv Physiol Educ. 2008;32(2):120-126. doi: 10.1152/advan.90111.2008.
  • Lindsay R. The menopause: sex steroids and osteoporosis. Clin Obstet Gynecol. 1987;30(4):847-859.
  • Walsh CA, Bowler WB, Bilbe G, et al. Effects of PTH on PTHrP gene expression in human osteoblasts: up-regulation with the kinetics of an immediate early gene. Biochem Biophys Res Commun. 1997;239(1):155-159. doi: 10.1006/bbrc.1997.7351.
  • Prior JC. Progesterone as a bone-trophic hormone. Endocr Rev. 1990;11(2):386-398. doi: 10.1210/edrv-11-2-386.
  • Балан В.Е., Орлова С.А., Кузнецов С.Ю., и др. Влияние лечения эндометриоза диеногестом в течение года на минеральную плотность костной ткани // Проблемы репродукции. - 2017. - Т. 23. - № 6. - С. 66-70. [Balan VE, Orlova SA, Kuznetsov SU, et al. Effects of dienogest on bone mineral density during the year of endometriosis treatment. Modern Reproductive Technologies. 2017;23(6):66-70. (In Russ.)]. doi: 10.17116/repro201723666-70.
  • Кузнецова Л.В. Сопоставление эффективности эстроген-гестагенных препаратов и алендроната в терапии остеопении у женщин постменопаузального возраста: Автореф. дис. … канд. мед. наук. - СПб., 2006. [Kuznetsova LV. Comparison of the efficacy of estrogen-progestogen and alendronate in the treatment of osteopenia in postmenopausal women. [dissertation] Saint Petersburg; 2006. (In Russ.)]
  • Pacifici R. Cytokines, estrogen, and postmenopausal osteoporosis - the second decade. Endocrinology. 1998;139(6):2659-2661. doi: 10.1210/endo.139.6.6087.
  • Lerner UH. Inflammation-induced bone remodeling in periodontal disease and the influence of post-menopausal osteoporosis. J Dent Res. 2006;85(7):596-607. doi: 10.1177/154405910608500704.
  • Goderie-Plomp HW, van der Klift M, de Ronde W, et al. Endogenous sex hormones, sex hormone-binding globulin, and the risk of incident vertebral fractures in elderly men and women: the Rotterdam Study. J Clin Endocrinol Metab. 2004;89(7):3261-3269. doi: 10.1210/jc.2002-022041.
  • Manolagas SC. Sex Steroids and Bone. Recent Prog Horm Res. 2002;57(1):385-409. doi: 10.1210/rp.57.1.385.
  • O’Brien CA, Jia D, Plotkin LI, et al. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology. 2004;145(4):1835-1841. doi: 10.1210/en.2003-0990.
  • Lin SC, Yamate T, Taguchi Y, et al. Regulation of the gp80 and gp130 subunits of the IL-6 receptor by sex steroids in the murine bone marrow. J Clin Invest. 1997;100(8):1980-1990. doi: 10.1172/JCI119729.
  • Liang M, Liao Ey, Xu X, et al. Effects of Progesterone and 18-Methyl Levonorgestrel on Osteoblastic Cells. Endocrine Research. 2009;29(4):483-501. doi: 10.1081/erc-120026954.
  • Довжикова И.В., Луценко М.Т. Современные представления о роли прогестерона (Обзор литературы) // Бюллетень физиологии и патологии дыхания. - 2016. - № 60. - C. 94-104. [Dovzhikova IV, Lutsenko MT. Modern concepts of progesterone role (Review). Byulleten’ fiziologii i patologii dykhaniya. 2016;(60):94-104. (In Russ.)]. doi: 10.12737/20128.
  • Апетов С.С., Калинченко С.Ю., Ворслов Л.О. Роль гестагенов в заместительной гормональной терапии. Нужны ли гестагены при хирургической менопаузе? // Лечащий врач. - 2013. - № 11. - С. 46-49. [Apetov SS, Kalinchenko SY, Vorslov LO. The role of gestagens in hormone replacement therapy. Do you need gestagens for surgical menopause? Practicioner. 2013;(11):46-49. (In Russ.)]
  • Shea B, Wells G, Cranney A, et al. Meta-analyses of therapies for postmenopausal osteoporosis. VII. Meta-analysis of calcium supplementation for the prevention of postmenopausal osteoporosis. Endocr Rev. 2002;23(4):552-559. doi: 10.1210/er.2001-7002.
  • Papadimitropoulos E, Wells G, Shea B, et al. Meta-analyses of therapies for postmenopausal osteoporosis. VIII: Meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. Endocr Rev. 2002;23(4):560-569. doi: 10.1210/er.2001-8002.
  • Naessen T, Olsson S-E, Gudmundson J. Differential effects on bone density of progestogen-only methods for contraception in premenopausal women. Contraception. 1995;52(1):35-39. doi: 10.1016/0010-7824(95)00121-p.
  • Lopez LM, Grimes DA, Schulz KF, et al. Steroidal contraceptives: effect on bone fractures in women. Cochrane Database Syst Rev. 2014(6):CD006033. doi: 10.1002/14651858.CD006033.pub5.
  • Lanza LL, McQuay LJ, Rothman KJ, et al. Use of depot medroxyprogesterone acetate contraception and incidence of bone fracture. Obstet Gynecol. 2013;121(3):593-600. doi: 10.1097/AOG.0b013e318283d1a1.
  • Speroff L. The Comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART Study). JAMA. 1996;276(17):1397. doi: 10.1001/jama.1996.03540170041030.
  • Серов В.Н. Современная гормональная контрацепция // Фарматека. - 2003. - № 11. - С. 33-38. [Serov VN. Modern hormonal contraception. Farmateka. 2003;(11):33-38. (In Russ.)]
  • Kuohung W, Borgatta L, Stubblefield P. Low-dose oral contraceptives and bone mineral density: an evidence-based analysis. Contraception. 2000;61(2):77-82. doi: 10.1016/s0010-7824(00)00086-x.
  • Reed SD, Scholes D, LaCroix AZ, et al. Longitudinal changes in bone density in relation to oral contraceptive use. Contraception. 2003;68(3):177-182. doi: 10.1016/s0010-7824(03)00147-1.
  • Endrikat J, Mih E, Dusterberg B, et al. A 3-year double-blind, randomized, controlled study on the influence of two oral contraceptives containing either 20 microg or 30 microg ethinylestradiol in combination with levonorgestrel on bone mineral density. Contraception. 2004;69(3):179-187. doi: 10.1016/j.contraception.2003.10.002.
  • Wei S, Winzenberg T, Laslett LL, et al. Oral contraceptive use and bone. Curr Osteoporos Rep. 2011;9(1):6-11. doi: 10.1007/s11914-010-0037-9.
  • Подзолкова Н.М., Коренная В.В. Лечебные эффекты гормональных контрацептивов // Гинекология. - 2012. - Т. 14. - № 2. - С. 57-61. [Podzolkova NM, Korennaya VV. Therapeutic effects of hormonal contraceptives. Ginekologiya. 2012;14(2):57-61. (In Russ.)]
  • Scholes D, LaCroix AZ, Hubbard RA, et al. Oral contraceptive use and fracture risk around the menopausal transition. Menopause. 2016;23(2):166-174. doi: 10.1097/GME.0000000000000595.
  • Gordon CM, Grace E, Emans SJ, et al. Effects of oral dehydroepiandrosterone on bone density in young women with anorexianervosa: a randomized trial. J Clin Endocrinol Metab. 2002;87(11):4935-4941. doi: 10.1210/jc.2002-020545.
  • Going S, Lohman T, Houtkooper L, et al. Effects of exercise on bone mineral density in calcium-replete postmenopausal women with and without hormone replacement therapy. Osteoporos Int. 2003;14(8):637-643. doi: 10.1007/s00198-003-1436-x.
  • Зазерская И.Е., Кузнецова Л.В., Дячук А.В., и др. Оценка эффективности применения половых стероидов в лечении остеопении и остеопороза в раннем постменопаузальном периоде (трехлетнее исследование) // Журнал акушерства и женских болезней. - 2008. - Т. 57. - № 1. - C. 66-75. [Zazerskaya IE, Kuznetzova LV, Dyachuk AV, et al. Sex steroids application effectiveness evaluation in early postmenopausal osteoporosis and osteopenia treatment (3-Year Study). Journal of Obstetrics and Women’s Diseases. 2008;57(1):66-75. (In Russ.)]
  • Steiniche T, Hasling C, Charles P, et al. A randomized study on the effects of estrogen/gestagen or high dose oral calcium on trabecular bone remodeling in postmenopausal osteoporosis. Bone. 1989;10(5):313-320. doi: 10.1016/8756-3282(89)90126-9.
  • Paschalis EP, Boskey AL, Kassem M, Eriksen EF. Effect of hormone replacement therapy on bone quality in early postmenopausal women. J Bone Miner Res. 2003;18(6):955-959. doi: 10.1359/jbmr.2003.18.6.955.
  • Сметник В.П., Сметник А.А. Эстрогены и костная ткань // Фарматека. - 2013. - № 12. - C. 17-21. [Smetnik VP, Smetnik AA. Estrogens and bone tissue. Farmateka. 2013;(12):17-21. (In Russ.)]
  • Casper RF. Estrogen with interrupted progestin HRT: a review of experimental and clinical studies. Maturitas. 2000;34(2):97-108. doi: 10.1016/s0378-5122(99)00076-6.
  • Liu JH, Muse KN. The effects of progestins on bone density and bone metabolism in postmenopausal women: a randomized controlled trial. Am J Obstet Gynecol. 2005;192(4):1316-1323; discussion 1323-1314. doi: 10.1016/j.ajog.2004.12.067.
  • Baber RJ, Panay N, Fenton A, Group IMSW. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016;19(2):109-150. doi: 10.3109/13697137.2015.1129166.
  • Zaiem F, Alahdab F, Al Nofal A, et al. Oral versus transdermal estrogen in turner syndrome: A systematic review and meta-analysis. Endocr Pract. 2017;23(4):408-421. doi: 10.4158/EP161622.OR.
  • Heikkinen J, Vaheri R, Haapalahti J, Timonen U. A 10-year follow-up of the effect of continuous-combined hormone replacement therapy and its discontinuation on bone in postmenopausal women. Menopause Int. 2008;14(2):70-77. doi: 10.1258/mi.2008.008008.
  • Хирургическая менопауза: пособие для врачей / Под ред. В.И. Кулакова, В.П. Сметника. - М., 2003. [Surgical menopause: a manual for doctors. Ed by V.I. Kulakov, V.P. Smetnik. Moscow; 2003. (In Russ.)]
  • Leader A, Ayzenfeld RH, Lishner M, et al. Thyrotropin levels within the lower normal range are associated with an increased risk of hip fractures in euthyroid women, but not men, over the age of 65 years. J Clin Endocrinol Metab. 2014;99(8):2665-2673. doi: 10.1210/ jc.2013-2474.
  • Blum MR, Bauer DC, Collet TH, et al. Subclinical thyroid dysfunction and fracture risk: a meta-analysis. JAMA. 2015;313(20):2055-2065. doi: 10.1001/jama.2015.5161.
  • Ding B, Zhang Y, Li Q, et al. Low thyroid stimulating hormone levels are associated with low bone mineral density in femoral neck in elderly women. Arch Med Res. 2016;47(4):310-314. doi: 10.1016/j.arcmed.2016.07.009.
  • Kim TH, Joung JY, Kang M, et al. A modest protective effect of thyrotropin against bone loss is associated with plasma triiodothyronine levels. PLoS One. 2015;10(12):e0145292. doi: 10.1371/journal.pone.0145292.
  • Murphy E, Gluer CC, Reid DM, et al. Thyroid function within the upper normal range is associated with reduced bone mineral density and an increased risk of nonvertebral fractures in healthy euthyroid postmenopausal women. J Clin Endocrinol Metab. 2010;95(7):3173-3181. doi: 10.1210/jc.2009-2630.
  • Pejin R, Curic N, Kovacev-Zavisic B, Todorovic-Djilas L. Bone metabolism during substitution therapy of primary hypothyroidism. Med Pregl. 2009;62(9-10):407-411. doi: 10.2298/mpns0910407p.
  • Верткин А.Л., Наумов А.В. Шедевры художественных галерей для докторов. Остеопороз. - М.: Эксмо, 2011. [Vertkin AL, Naumov AV. Masterpieces of art galleries for doctors. Osteoporosis. Moscow: Эксмо; 2011. (In Russ.)]
  • Faber, Jensen, Petersen, et al. Normalization of serum thyrotrophin by means of radioiodine treatment in subclinical hyperthyroidism: effect on bone loss in postmenopausal women. Clin Endocrinol. 1998;48(3):285-290. doi: 10.1046/j.1365-2265.1998.00427.x.
  • Mudde AH, Houben AJHM, Kruseman ACN. Bone metabolism during anti-thyroid drug treatment of endogenous subclinical hyperthyroidism. Clin Endocrinol. 1994;41(4):421-424. doi: 10.1111/j.1365-2265.1994.tb02571.x.
  • Lin JD, Pei D, Hsia TL, et al. The relationship between thyroid function and bone mineral density in euthyroid healthy subjects in Taiwan. Endocr Res. 2011;36(1):1-8. doi: 10.3109/07435800.2010.514877.
  • Garin MC, Arnold AM, Lee JS, et al. Subclinical thyroid dysfunction and hip fracture and bone mineral density in older adults: the cardiovascular health study. J Clin Endocrinol Metab. 2014;99(8):2657-2664. doi: 10.1210/jc.2014-1051.
  • Wirth CD, Blum MR, da Costa BR, et al. Subclinical thyroid dysfunction and the risk for fractures: a systematic review and meta-analysis. Ann Intern Med. 2014;161(3):189-199. doi: 10.7326/M14-0125.
  • McIlwain HH. Glucocorticoid-induced osteoporosis: pathogenesis, diagnosis, and management. Preventive Medicine. 2003;36(2):243-249. doi: 10.1016/s0091-7435(02)00019-1.
  • Capozzi A, Casa SD, Altieri B, Pontecorvi A. Chronic low-dose glucocorticoid inhalatory therapy as a cause of bone loss in a young man: case report. Clin Cases Miner Bone Metab. 2013;10(3):199-202.

Views

Abstract - 20

PDF (Russian) - 13

PlumX


Copyright (c) 2018 Shalina M.A., Yarmolinskaya M.I., Abashova E.I.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.